Acadia Pharmaceuticals | ACAD - Nettoeinkommen





Nettoeinkommen Veränderung Datum
Acadia Pharmaceuticals USD 53.52M 22.02M 2026-09
ALKERMES USD 16.29M 15.79M 2026-09
Alnylam Pharmaceuticals USD 2.17B 2B 2026-09
Biogen USD 97.5M 222M 2026-06
BioMarin Pharmaceutical USD -122.83M 167.59M 2026-09
Bristol-Myers Squibb USD 2.16B 1.16B 2026-09
Cara Therapeutics USD -6.8M 1.28M 2026-03
Corcept Therapeutics USD 124.49M 82.35M 2026-09
Cytokinetics USD -190.07M 8.69M 2026-09
Eisai JPY 18.24B 21.49B 2026-06
Eli Lilly USD 7.1B 301M 2026-06
Incyte USD -784.8M 1.37B 2026-09
J&J USD 210M 5.32B 2026-09
Moderna USD 162M 944M 2026-09
Neurocrine Biosciences USD 144.4M 53.5M 2026-06
Pfizer USD 3.24B 3.49B 2026-09
Prothena USD -18.58M 51.3M 2026-06
PTC Therapeutics USD 83.5M 86.3M 2026-06
Sarepta Therapeutics USD -28.46M 23.57M 2026-09
Ultragenyx Pharmaceutical USD -118M 26M 2026-09
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12
Vertex Pharmaceuticals USD 653.6M 446.2M 2026-09